INTRODUCTION
The immunostimulatory activity of bacterial DNA was first reported in 1984 (1) . This effect is mediated by unmethylated CpG motifs within the DNA and can also be observed with synthetic oligodeoxynucleotides (ODNs) 1 containing these CpG sites (2) . The ability of CpG sequences to stimulate the immune system is mainly due to their effects on antigen-presenting cells. (reviewed in (3, 4) ). CpG ODNs have also been shown to activate T cells via direct (5, 6) and indirect mechanisms (7, 8) .
CpG ODNs act through binding to Toll like receptor 9 (TLR9) (9) , one of 10 members of the Toll-like receptor (TLR) family identified in humans (10) . TLRs belong to the superfamily of pattern-recognition receptors (PRRs), which are involved in generating innate immune responses. TLR9 is expressed primarily in B cells and plasmacytoid dentritic cells (pDCs) (9, (11) (12) (13) but a weak TLR9 expression has also been observed in T cells (12) .
The immunostimulatory activity of CpG ODNs can be used therapeutically to enhance specific immune responses both in vaccinations and acute infections and has led to promising results for the treatment of various pathogens, including retroviruses (14) (15) (16) (17) (18) (19) . Stimulating the immune system during HIV infection may not only be useful in enhancing antiviral immune responses but may also resolve the problem of viral latency in antiviral treatment. Highly active antiretroviral therapy (HAART) has had impressive results in the past few years, effectively suppressing virus replication in many patients and reducing virus titers to below clinical detection limits (20) (21) (22) . However, as soon as antiviral therapy is interrupted the virus load increases again requiring HIV patients to receive life-long maintenance therapy (23) (24) (25) . Latent reservoirs, such as infected memory T cells, contribute to this viral by guest on November 17, 2017 http://www.jbc.org/ Downloaded from 4 reemergence (26) and it is estimated that up to 60 years would be required to eliminate these reservoirs by use of HAART alone (27, 28) .
It has been proposed that treatment with a combination of cytokines could stimulate the latent reservoirs and thus render them vulnerable to antiviral therapy (29) . Clinical studies have been conducted using IL-2 or OKT3 in order to restimulate HIV from its latent reservoirs (30, 31) .
Here we show that CpG oligodeoxynucleotides directly stimulate HIV replication in latently infected human T cells. The results of our study help to clarify the role of TLR9 in HIV replication and provide a new potential approach to eradicate latent HIV in infected patients treated with antiretroviral therapy.
EXPERIMENTAL PROCEDURES

Cells, viruses, cell culture and reagents.
The latently HIV infected T cell lines ACH-2 (32) and J1.1 (33) and the uninfected T cell lines A3.01 (34) and Jurkat E6-1 (35) , were cultured at 37° in 5% CO 2 atmosphere in RPMI 1640 (Invitrogen, Karlsruhe, Germany), containing 10% FCS, were preincubated with the extracts for 30 minutes on ice before addition of the radiolabelled probe. For densitometric quantification of NF-kB activation, the intensity of NF-kB bands compared to background was determined with the software Quantity One (BioRad, Munich, Germany).
RESULTS
In this study we have analyzed the effects of CpG oligodeoxynucleotides (ODNs) on latent HIV infection in human T cells. We have exposed latently infected ACH-2 cells (Fig. 2) .
In contrast to ACH-2 cells, the latently-infected Jurkat clone J1.1 did not show enhancement of virus replication following CpG-treatment (Fig. 3) . As a positive control we have used TPA/ionomycin to show that the provirus in J1.1 cells can be activated. Our findings are consistent with previous studies in which it was reported that Jurkat T cells are insensitive towards CpG-signaling, such as activation of NF-kB (11) . Since J1.1 cells were positive for TLR9 mRNA (data not shown) and express TLR9 protein (Fig. 2B) we suggest that a signaling defect is either located downstream of the receptor or that additional factors (e.g. costimulatory events) are necessary to observe TLR9 signaling in these cells.
Binding of CpG ODNs to TLR9 occurs after cellular uptake of the DNA and requires endosomal acidification (37) . Chloroquine, an inhibitor of endosomal acidification, blocks TLR9 signaling and is therefore being used to study TLR9 activity (37) (38) (39) (40) 
NF-kB is an important transcription factor for replication of HIV (41). Moreover, TLR9
signaling is known to activate NF-kB in antigen presenting cells (42, 43) . To address the role of NF-kB in TLR9-induced reactivation of HIV, we analyzed cellular extracts of CpG-treated ACH-2 cells by EMSA. Treatment with CpG ODN 2006 activated the p65/p50 NF-kB heterodimer. Increased DNA binding was detectable at 4 hours, reaching a maximum at 8 hours and declining thereafter (Fig. 6B,C) . In parallel to the NF-kB studies, we determined HIV expression by flow cytometry. As shown in figure   6A , NF-kB induction preceded HIV expression, suggesting that CpG-induced HIV replication was initiated by NF-kB. It had previously been shown that CpG ODNs do not activate NF-kB in Jurkat cells, which correlates nicely with the inability of CpG ODNs to reactivate HIV in these cells (11) . In contrast, CpG ODNs activated NF-kB in the uninfected A3.01 T cell line, indicating that CpG-triggered signal transduction in these T cells is not dependent on proviral infection but can also be observed in uninfected cells (Fig. 7) . A further characterization of the NF-kB complexes showed that both the p50 homodimer and the p50/p65 heterodimer were formed in A3.01 T cells following CpG-treatment (Fig. 7A) . The same NF-kB complexes have also been found in CpG-stimulated B cells (44) 
